Neutral
Charles River Laboratories (CRL) has seen its share price recover recently, despite being down year-to-date. While one narrative suggests the stock is...
Charles River Laboratories (NYSE: CRL) director James C. Foster reported exempt, bona fide gifts and trust transfers totaling 366,722 shares of common...
Neutral
Charles River Laboratories (CRL) CEO Birgit Girshick reported exempt transfers of 6,772 shares, primarily structured as bona fide gifts rather than ma...
Charles River Laboratories International recently presented its "Pathway to Purpose" framework and ongoing portfolio reshaping, including divestitures...
Bullish
Charles River Laboratories International, Inc. (CRL) outlined a strategy at the 46th Annual William Blair Growth Stock Conference emphasizing operatio...
Neutral
Charles River Laboratories International, Inc. (NYSE: CRL) announced it will present at two upcoming conferences: the William Blair 46th Annual Growth...
Neutral
Charles River Laboratories International, Inc. (NYSE: CRL) announced it would present at the William Blair 46th Annual Growth Stock Conference on June...
Charles River Laboratories (CRL) reported first-quarter results showing modest revenue growth but a net loss and increased impairments, alongside a ra...
Charles River Laboratories International (NYSE:CRL) has partnered with MEDIPOST to expand its cell therapy development and commercialization services ...